Close Menu

Cellecta

The IP is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.

The company aims to commercialize the platform and related services by late 2018.

Using enhancements to RT-PCR, the firm is able to detect all protein-coding genes in a single-tube multiplex reaction, reducing costs for large-scale projects.

The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.

The company said the library will be made freely available to academic and non-profit investigators through the DECIPHER Project.

Exiqon, Cellecta

The company will use the NCI funding to discover and validate gene targets involved in breast cancer that may affect a panel of epithelial cells involved in breast cancer.

Cellecta

Pages

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.